MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript

SA Transcripts159.33K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity April 16, 2026 8:00 AM EDT Company Participants Alexandria Forbes - CEO, President & Director Conference Call Participants David OwensMichael BrennanAlec Stranahan - BofA Securities, Research DivisionChristopher Raymond - Raymond James & Associates, Inc., Research DivisionAshleigh Acker - Piper Sandler & Co., Research DivisionElemer Piros - Lucid Capital Markets, LLC, Research DivisionDaniil Gataulin - Chardan Capital Markets, LLC, Research DivisionLisa Walter - RBC Capital Markets, Research Division Presentation Operator Good morning, and welcome to the MeiraGTx program update. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the MeiraGTx website following the conclusion of the event. I'd now like to turn the call over to Zandy Forbes, President and Chief Executive Officer of MeiraGTx. Please go ahead, Zandy. Alexandria ForbesCEO, President & Director Thank you, everyone, for joining us this morning. Today, we are presenting the full 3-year data from our Phase I study of AAV-AQP1 for the treatment of persistent, moderate-to-severe, radiation-induced xerostomia or RIX, following radiation treatment for head and neck cancer. We will also provide an update on the commercial opportunity for this potential therapy. Be aware that we're making forward-looking statements, so please read this slide. On the agenda for today, I will first introduce the disease, go over the etiology of the condition and the mechanism of action of AAV-AQP1 therapy. I will give a quick recap of the Phase I 12-month data and then present the full 3-year data, which shows robust durability and within patient consistency over 3 years. We have 2 study investigators speaking today about the disease burden, the patient experience and importantly, their hands-on experience of delivering this therapy in our clinical trials. Following the physician's talks, I will be